Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHLW (Japan) approval for Phesgo, the fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast and colorectal cancer – Chugai

Written by | 30 Sep 2023

Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for Subcutaneous Injection MA, IN… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.